<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972946</url>
  </required_header>
  <id_info>
    <org_study_id>2007/R/CAR/15.2</org_study_id>
    <nct_id>NCT00972946</nct_id>
  </id_info>
  <brief_title>Cell Tracking Using Superparamagnetic Particles of Iron Oxide (SPIO) and Magnetic Resonance Imaging (MRI) - A Pilot Study</brief_title>
  <official_title>The Use of Magnetic Resonance Imaging and Superparamagnetic Particles of Iron Oxide in Cardiovascular Disease - a Pilot Study in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal College of Surgeons of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Translational Medicine Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ability to label specific cells and image their natural movements in vivo would allow
      researchers to investigate the mechanisms of disease progression. In addition, cell-based
      therapy, especially stem cell therapy, requires non-invasive monitoring of transplanted cells
      to follow their bio-distribution and biological function. Because of recent interest in stem
      cell treatment, several methods have been investigated for in vivo cell tracking. The
      investigators propose to assess whether the magnetic resonance imaging (MRI) contrast agent
      Endorem (superparamagnetic particles of iron oxide) can be used to label cells for in vivo
      tracking using MRI. The investigators will use 20 healthy human volunteers to:

        1. Assess the feasibility of imaging Endorem-labelled cells in vivo

        2. Compare the distribution of Endorem-labelled cells with that of intravenous injection of
           Endorem
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in signal intensity in the region of interest on MRI scanning</measure>
    <time_frame>0 hours, 24 hours, 48 hours, 5-7 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Administration of labelled cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI scanning before and after administration of iron-labelled cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of Endorem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI scanning before and after intravenous administration of Endorem</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Administration of autologous Endorem-labelled mononuclear cells intravenously</intervention_name>
    <description>single dose</description>
    <arm_group_label>Administration of labelled cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of Endorem</intervention_name>
    <description>single dose, intravenous</description>
    <arm_group_label>Administration of Endorem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  Age &gt;18 years

        Exclusion Criteria:

          -  Pregnancy

          -  Contraindication to MRI scanning (detected by safety questionnaire) including severe
             claustrophobia

          -  Inability or refusal to give informed consent

          -  Renal or hepatic dysfunction

          -  HIV/hepatitis B/ hepatitis C/ HTLV/ syphilis

          -  Intercurrent illness

          -  Blood dyscrasias
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David E Newby</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer MJ Richards, MBChB BSc MRCS</last_name>
    <phone>0131 242 3621</phone>
    <email>jenny.richards@ed.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David E Newby</last_name>
    <phone>0131 242 6515</phone>
    <email>d.e.newby@ed.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Edinburgh/Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <last_update_submitted>September 8, 2009</last_update_submitted>
  <last_update_submitted_qc>September 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Elspeth Currie</name_title>
    <organization>University of Edinburgh</organization>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>SPIO</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

